Estimations des analystes de Wall Street pour Protagonist Therapeutics, Inc. (PTGX): objectif de cours de consensus, recommandations achat/conserver/vente et prévisions de revenus, BPA et EBITDA pour les prochains exercices.
Surprises de Résultats Récentes
| Date | BPA Réel | BPA Estimé | vs Est. |
|---|---|---|---|
| 2026-11-05 | $2.43 | ||
| 2026-08-05 | $2.29 | $2.23 | +2.7% |
| 2026-05-05 | $0.05 | $-0.65 | +107.7% |
| 2026-02-25 | $-0.69 | $-0.53 | -30.2% |
| 2025-11-06 | $-0.62 | $-0.59 | -5.1% |
| 2025-08-06 | $-0.55 | $-0.53 | -3.8% |
| 2025-05-06 | $-0.19 | $-0.50 | +62.0% |
| 2025-02-21 | $1.98 | $0.06 | +3200.0% |
Ratios de valorisation
| Prix / Valeur comptable | 8.71 |
| EV / EBITDA | -42.43 |
| Rendement du dividende | 0.00% |
Compte de Résultat (10 ans)
| Année | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenus | 0 | $20.1M | $30.9M | $231000 | $28.6M | $27.4M | $26.6M | $60.0M | $434.4M | $46.0M |
| Coût des Ventes | $317000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $1.2M |
| Marge Brute | -$317000 | $20.1M | $30.9M | $231000 | $28.6M | $27.4M | $26.6M | $60.0M | $434.4M | $44.8M |
| R&D | $25.7M | $46.2M | $59.5M | $65.0M | $76.0M | $126.0M | $126.2M | $120.2M | $138.1M | $159.3M |
| Frais Généraux | $7.0M | $11.8M | $13.7M | $15.7M | $18.6M | $27.2M | $31.7M | $33.5M | $43.5M | $44.9M |
| Charges Opérationnelles | $32.7M | $58.0M | $73.2M | $80.8M | $93.1M | $153.2M | $158.0M | $153.7M | $181.6M | $202.9M |
| Résultat Opérationnel | -$32.7M | -$37.9M | -$42.3M | -$80.5M | -$64.5M | -$125.8M | -$131.4M | -$93.7M | $252.8M | -$158.1M |
| EBITDA | -$32.3M | -$36.6M | -$39.2M | -$77.0M | -$63.6M | -$122.8M | -$124.0M | -$75.6M | $280.2M | -$128.1M |
| Charges d'Intérêt | 0 | 0 | 0 | $169000 | $598000 | 0 | 0 | 0 | 0 | 0 |
| Résultat Avant Impôts | -$37.2M | -$37.0M | -$39.7M | -$77.9M | -$64.8M | -$125.6M | -$127.4M | -$79.0M | $279.4M | -$129.3M |
| Impôts | 0 | 0 | -$799000 | -$691000 | $1.3M | 0 | 0 | 0 | $4.2M | $838000 |
| Résultat Net | -$37.2M | -$37.0M | -$38.9M | -$77.2M | -$66.2M | -$125.6M | -$127.4M | -$79.0M | $275.2M | -$130.1M |
| BPA | $-5.72 | $-2.09 | $-1.74 | $-2.98 | $-1.92 | $-2.65 | $-2.52 | $-1.39 | $4.47 | $-2.05 |
| BPA Dilué | $-5.72 | $-2.09 | $-1.74 | $-2.98 | $-1.92 | $-2.65 | $-2.52 | $-1.39 | $4.23 | $-2.05 |
| Actions en Circulation (Diluées) | $6.5M | $17.7M | $22.4M | $25.9M | $34.4M | $46.3M | $49.0M | $56.8M | $65.1M | $63.6M |
Prix
| Prix | $142.84 |
| Capitalisation | $9.2B |
| Bourse | NASDAQ |
| Pays | US |
Entreprises liées: ACLX · AKRO · ALKS · CRNX · IMVT · KYMR · NAMS
Explorer le secteur: Healthcare · Biotechnology
Plus de sections de PTGX: Vue d'ensemble · Financiers · Valorisation · Statistiques · Technique · Actionnariat · Actualités · Événements
Découvrir plus: Radar — signaux d'actions sous-évaluées · Académie d'Investissement — apprenez à analyser les actions